Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
NCT ID: NCT05973838
Last Updated: 2025-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
180 participants
INTERVENTIONAL
2023-06-15
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peer-Delivered Behavioral Activation for Methadone Adherence - Pilot Phase
NCT04248933
Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence
NCT05299515
FOREward Together: Training Peer Recovery Coaches to Promote Retention and Adherence to MOUD
NCT05098795
Peer Recovery Support Services for Individuals in Recovery Residences on MOUD
NCT05616949
Opioid Treatment and Peer Recovery Support
NCT04978168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Behavioral activation (BA) may be a feasible, scalable, reinforcement-based approach for improving OUD treatment retention and reducing polysubstance use in underserved areas. By targeting increases in positive reinforcement, BA has been found to be effective for improving SUD treatment retention, preventing future relapse, including for stimulant use specifically, and improving medication adherence (i.e., for HIV) among low-income, minority populations with SUD as well as depression, which is a barrier to MOUD retention. BA has been shown to be feasibly delivered by peers and community health workers.
This study proposes to evaluate the effectiveness, implementation, and cost-effectiveness of an adapted PRS-delivered BA approach on the TM-MTU ("Peer Activate-MTU") compared to enhanced treatment as usual (ETAU; facilitated referrals and general PRS support) for patients with OUD and other polysubstance use receiving telemedicine buprenorphine. The investigators propose a randomized Type 1 hybrid effectiveness-implementation trial (n=180) to evaluate Peer Activate-MTU compared to ETAU. Specific aims are to evaluate the effectiveness of Peer Activate-MTU over 12-months on OUD treatment retention and polysubstance use. The investigators will also evaluate the implementation of Peer-Active-MTU, including feasibility, acceptability, fidelity, and adoption guided by RE-AIM.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Peer-Delivered Behavioral Activation ("Peer Activate")
Participants in the Peer Activate intervention will receive a PRS-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention and reduce polysubstance use.
Peer-Delivered Behavioral Activation ("Peer Activate")
The PRS-delivered Peer Activate intervention will consist of approximately six weekly "core" sessions (approximately 30 minutes-1 hour), and then 6 optional "booster" sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention.
Treatment As Usual
Participants in the TAU group will receive enhanced treatment as usual, defined as MTU services as usual enhanced with additional community referrals and follow-ups on those referrals, in addition to regular meetings with an addiction medicine physician and PRS on the MTU. Standard PRS contact typically includes connection to local resources and general peer support as needed.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peer-Delivered Behavioral Activation ("Peer Activate")
The PRS-delivered Peer Activate intervention will consist of approximately six weekly "core" sessions (approximately 30 minutes-1 hour), and then 6 optional "booster" sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Inability to understand the study and provide informed consent in English
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland, Baltimore
OTHER
Weill Medical College of Cornell University
OTHER
National Institute on Drug Abuse (NIDA)
NIH
University of Maryland, College Park
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jessica Magidson
Director and Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica F Magidson, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, College Park
Sarah M Kattakuzhy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HIPS Clinic
Washington D.C., District of Columbia, United States
University of Maryland Baltimore (UMD Drug Treatment Center)
Baltimore, Maryland, United States
University of Maryland, College Park
College Park, Maryland, United States
Caroline County Behavioral Health
Denton, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ghertner R. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug Alcohol Depend. 2019 Nov 1;204:107527. doi: 10.1016/j.drugalcdep.2019.06.029. Epub 2019 Aug 30.
Propst F, Rosenberg MP, Vande Woude GF. Proto-oncogene expression in germ cell development. Trends Genet. 1988 Jul;4(7):183-7. doi: 10.1016/0168-9525(88)90073-x. No abstract available.
McGeachie RE, Ford WJ, Nelson MJ, Elias D, Goldberg ME. Neuroradiology case of the day. AJR Am J Roentgenol. 1987 May;148(5):1053-7. doi: 10.2214/ajr.148.5.1053. No abstract available.
Reger KM, Hunter TB. Case of the month No. 67. Watch battery ingestion. Ariz Med. 1983 Aug;40(8):559-60. No abstract available.
Lees P, Allsup FC. Influence of oxytocin and growth hormone on the actions of aldosterone in the rat. Arch Int Pharmacodyn Ther. 1969 Feb;177(2):457-71. No abstract available.
Yamazaki F, Donaldson EM. Involvement of gonadotropin and steroid hormones in the spermiation of the goldfish (Carassius auratus). Gen Comp Endocrinol. 1969 Jun;12(3):491-7. doi: 10.1016/0016-6480(69)90165-8. No abstract available.
Koper S, Mucha M. A cineradiographic method for recording the function of the oesophageal groove in lambs. Acta Physiol Pol. 1983 Sep-Dec;34(5-6):539-45.
Delamothe T. Nursing grievances. I: Voting with their feet. Br Med J (Clin Res Ed). 1988 Jan 2;296(6614):25-8. doi: 10.1136/bmj.296.6614.25. No abstract available.
Tull MT, Berghoff CR, Bardeen JR, Schoenleber M, Konkle-Parker DJ. An Initial Open Trial of a Brief Behavioral Activation Treatment for Depression and Medication Adherence in HIV-Infected Patients. Behav Modif. 2018 Mar;42(2):196-209. doi: 10.1177/0145445517723901. Epub 2017 Aug 11.
Miyai K, Azukizawa M, Kumahara Y. Bioassay and immunoassay measurements of serum thyrotropin in primary hypothyroidism before and after the administration of thyrotropin releasing hormone. Horm Metab Res. 1974 Jan;6(1):9-12. doi: 10.1055/s-0028-1093894. No abstract available.
Kaye S. Insidious lead poisoning. Bol Asoc Med P R. 1967 Feb;59(2):63-70. No abstract available.
Richards DA, Ekers D, McMillan D, Taylor RS, Byford S, Warren FC, Barrett B, Farrand PA, Gilbody S, Kuyken W, O'Mahen H, Watkins ER, Wright KA, Hollon SD, Reed N, Rhodes S, Fletcher E, Finning K. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016 Aug 27;388(10047):871-80. doi: 10.1016/S0140-6736(16)31140-0. Epub 2016 Jul 23.
VanderWilde RS, Pritchard DJ. Adamantinoma of the tibia. Orthopedics. 1992 Aug;15(8):950-3. doi: 10.3928/0147-7447-19920801-15. No abstract available.
Davison A, Tibbits G, Shi ZG, Moon J. Active oxygen in neuromuscular disorders. Mol Cell Biochem. 1988 Dec;84(2):199-216. doi: 10.1007/BF00421055.
Mack KA, Jones CM, Ballesteros MF. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-United States. Am J Transplant. 2017 Dec;17(12):3241-3252. doi: 10.1111/ajt.14555.
Langabeer JR, Stotts AL, Cortez A, Tortolero G, Champagne-Langabeer T. Geographic proximity to buprenorphine treatment providers in the U.S. Drug Alcohol Depend. 2020 Aug 1;213:108131. doi: 10.1016/j.drugalcdep.2020.108131. Epub 2020 Jun 24.
Magidson JF, Kleinman MB, Bradley V, Anvari MS, Abidogun TM, Belcher AM, Greenblatt AD, Dean D, Hines A, Seitz-Brown CJ, Wagner M, Bennett M, Felton JW. Peer recovery specialist-delivered, behavioral activation intervention to improve retention in methadone treatment: Results from an open-label, Type 1 hybrid effectiveness-implementation pilot trial. Int J Drug Policy. 2022 Oct;108:103813. doi: 10.1016/j.drugpo.2022.103813. Epub 2022 Aug 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1953327
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.